Efficacy of Zinc-L-Carnosine (Polaprezinc) in Treating Infant Regurgitation: Results from a Two-Center Randomized Controlled Study - Summary - MDSpire

Efficacy of Zinc-L-Carnosine (Polaprezinc) in Treating Infant Regurgitation: Results from a Two-Center Randomized Controlled Study

  • By

  • Marisa Piccirillo

  • Maurizio Mennini

  • Enrico Felici

  • Angela Mauro

  • Luca Bernardo

  • Maria Elisabetta Baldassarre

  • Erika Renzi

  • Corrado De Vito

  • Silvia Furio

  • Marco Graziani

  • Giovanna Quatrale

  • Alessandro Ferretti

  • Giovanni Di Nardo

  • April 21, 2026

  • 0 min

Share

Objective:

To evaluate the clinical effectiveness and cost-effectiveness of Zinc-L-carnosine (Hepilor liquido®) compared to thickened formula in infants with persistent regurgitation.

Key Findings:
  • Both treatment groups showed significant improvement in I-GERQ-R scores at 8 weeks.
  • The Hepilor liquido® group had a greater reduction in regurgitation frequency.
  • Average treatment cost was significantly lower in the Hepilor liquido® group compared to the thickened formula, indicating a favorable safety profile with no severe adverse events recorded in either group.
Interpretation:

Zinc-L-carnosine is a safe and effective alternative to thickened formula for treating persistent infant regurgitation, with additional cost benefits that warrant further investigation.

Limitations:
  • The study was limited to a small sample size of 60 infants, which may introduce biases.
  • Results may not be generalizable beyond the studied population.
Conclusion:

Zinc-L-carnosine is a promising treatment option for infant regurgitation, warranting further investigation in larger cohorts to confirm its efficacy and safety.

Original Source(s)

Related Content